-40.4%
ACN vs MRNA
+34.8%
-75.2%
-68.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.4% | +5.4% | -2.0% | +3.1% |
| 7D | -1.5% | -1.1% | -0.4% | -1.5% |
| 30D | +2.1% | +126.1% | -124.0% | -4.2% |
| 3M | +11.1% | +190.0% | -178.9% | +2.3% |
| 6M | -6.8% | +157.2% | -164.1% | -13.6% |
| YTD | -30.0% | +388.2% | -418.2% | -38.7% |
| 1Y | -23.1% | +467.0% | -490.2% | -33.8% |
| 3Y | -40.4% | +36.1% | -76.5% | -47.4% |
| All | -40.4% | +34.8% | -75.2% | -47.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling